Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 11/20 | 0.83 |
| ▸ | MTTP | P55157 | 7/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | APOB | P04114 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12157791 | 0.97 | NPY2R (0.78) | NPY2RMTTPGAASMN1; SMN2CCR3 | |
| SCHEMBL12174432 | 0.93 | NPY2R (0.72) | NPY2RMTTPGAASMN1; SMN2CCR3 | |
| SCHEMBL12174516 | 0.93 | NPY2R (0.72) | NPY2RMTTPGAASMN1; SMN2CCR3 | |
| SCHEMBL12174502 | 0.92 | NPY2R (0.70) | NPY2RMTTPGAACCR3 | |
| SCHEMBL3136624 | 0.92 | NPY2R (0.70) | NPY2RMTTPGAASMN1; SMN2CCR3 | |
| SCHEMBL6582536 | 0.92 | NPY2R (0.70) | NPY2RMTTPGAASMN1; SMN2CCR3 | |
| SCHEMBL13522065 | 0.92 | NPY2R (0.70) | NPY2RMTTP | |
| SCHEMBL12174563 | 0.92 | NPY2R (0.70) | NPY2RMTTPGAASMN1; SMN2APOB | |
| SCHEMBL13522069 | 0.91 | NPY2R (0.69) | NPY2RMTTP | |
| SCHEMBL5742603 | 0.91 | NPY2R (0.68) | NPY2RMTTPGAAAPOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289971-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | claimed |
| WO-2001092241-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-06 | — | — | WO | claimed |
| US-8354402-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-15 | — | — | US | disclosed |
| US-8354402-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-15 | — | — | US | disclosed |
| US-8354402-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-15 | — | — | US | disclosed |
| US-20110269747-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2011-11-03 | — | — | US | disclosed |
| US-20110269747-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2011-11-03 | — | — | US | disclosed |
| US-20110269747-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2011-11-03 | — | — | US | disclosed |
| EP-1317431-B1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-20 | — | — | EP | disclosed |
| US-7642378-B2 | Lipid lowering biphenylcarboxamides | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-05 | — | — | US | disclosed |
| US-7528154-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICAL N.V. (BE) | 2009-05-05 | — | — | US | disclosed |
| US-7169796-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-30 | — | — | US | disclosed |
| US-7169796-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-30 | — | — | US | disclosed |
| US-20060241113-A1 | Polyarylcarboxamides useful as lipid lowering agents | MEERPOEL LIEVEN | 2006-10-26 | — | — | US | disclosed |
| US-20050159402-A1 | Polyarylcarboxamides useful as lipid lowering agents | MEERPOEL LIEVEN (BE) | 2005-07-21 | — | — | US | disclosed |
| US-6878724-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN-PHARMACEUTICA N.V. (BE) | 2005-04-12 | — | — | US | disclosed |
| US-20040024215-A1 | Benzamide derivatives and their use as apob-100 and mtp inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-02-05 | — | — | US | disclosed |
| US-20040014971-A1 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-22 | — | — | US | disclosed |
| EP-1289971-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092241-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159402-A1 | Polyarylcarboxamides useful as lipid lowering agents | LIPC, PNLIP, APOB | NPY2R 4187/4885MTTP 9/4885GAA 476/4885 |
| US-20040024215-A1 | Benzamide derivatives and their use as apob-100 and mtp inhibitors | APOB, APOL1, CETP | NPY2R 983/4885MTTP 6/4885GAA 1072/4885 |
| US-20060241113-A1 | Polyarylcarboxamides useful as lipid lowering agents | LIPC, PNLIP, APOB | NPY2R 4187/4885MTTP 9/4885GAA 476/4885 |
| US-20110269747-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | LIPC, PNLIP, APOB | NPY2R 4187/4885MTTP 9/4885GAA 476/4885 |
| US-20040014971-A1 | Polyarylcarboxamides useful as lipid lowering agents | SREBF1, LIPC, CPT1A | NPY2R 4449/4885MTTP 20/4885GAA 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.